Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Icon has observed an 11% increase in gross business awards on a sequential basis, driven by significant wins from biotech customers and the ongoing expansion of large pharmaceutical partnerships formed in the past 18 months. The company has successfully met or exceeded its financial targets related to the PRA acquisition, positioning itself favorably amidst funding environment uncertainties with a strong client and business mix. Additionally, Icon is well-positioned to benefit from the growth in the contract research organization (CRO) market, evidenced by an improving win rate within its client segments.

Bears say

Icon has revised its EBITDA margin expectations downward for the coming years, projecting margins in the high-19% range instead of the previously anticipated ~20%, signaling potential pressure on profitability. Additionally, various downside risks, including slowed clinical trial activity due to pharmaceutical company reprioritizations and uncertainty surrounding biotech funding, could negatively impact Icon's financial performance. The company's reliance on consistent revenue growth from clinical research is further complicated by external factors such as inflation and a slowdown in pharmaceutical R&D spending, adding to the negative outlook for its stock.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.